Sonja Levanat1, Maja Sabol, Vesna Musani, Petar Ozretic, Diana Trnski.
Abstract
BACKGROUND: Hedgehog signaling pathway is a developmental pathway mostly inactive in adult tissues, with the exception of stem cells. It is often found upregulated in various tumors, and associated with cancer stem cell maintenance.
METHODS: This review focuses on different aspects of Hedgehog activation in tumors, with special emphasis on ovarian tumors and their treatment.
RESULTS: Mutations in pathway components lead to a series of developmental malformations and syndromes. Aberrant activation of the pathway can be caused by mutations, noncanonical transcriptional regulation, or epigenetic changes.
CONCLUSION: This pathway is an interesting target in cancer therapy, especially when combined with therapies targeting other signaling pathways. Combination therapy can be used to bypass resistance or to target cancer stem cells in a more efficient way. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
BACKGROUND: Hedgehog signaling pathway is a developmental pathway mostly inactive in adult tissues, with the exception of stem cells. It is often found upregulated in various tumors, and associated with cancer stem cell maintenance.
METHODS: This review focuses on different aspects of Hedgehog activation in tumors, with special emphasis on ovarian tumors and their treatment.
RESULTS: Mutations in pathway components lead to a series of developmental malformations and syndromes. Aberrant activation of the pathway can be caused by mutations, noncanonical transcriptional regulation, or epigenetic changes.
CONCLUSION: This pathway is an interesting target in cancer therapy, especially when combined with therapies targeting other signaling pathways. Combination therapy can be used to bypass resistance or to target cancer stem cells in a more efficient way. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
Entities:
Keywords:
Hedgehog signaling; cyclopamine; methylation; miRNA; mutation; ovarian tumors; therapy
Mesh：
Substances：
Year: 2017
PMID： 27719639 DOI： 10.2174/1381612822666161006154705
Source DB: PubMed Journal: Curr Pharm Des ISSN： 1381-6128 Impact factor: 3.116